Kymera Therapeutics KYMR SEC Filings

NASDAQ KYMR
$134.84 -1.80 (-1.32%)
At close: Nov 11, 2026 · 4:00 PM EST
EDGAR Disclosures

SEC Filings

Source SEC EDGAR

Every SEC filing Kymera Therapeutics, Inc. (KYMR) has made, as reported on EDGAR — annual and quarterly reports, current reports, insider transactions and ownership disclosures. Filter by form group, form type or period, and open any filing or its index directly.

Form Type
# Form Type Form Group Accession Date Filing Index
110-QQuarterly & Annual Report0001193125-26-436975Oct 29, 2026 11:15 AM
28-KCurrent Report0001193125-26-436965Oct 29, 2026 11:10 AM
3SCHEDULE 13GBeneficial Ownership Report0002012383-26-003919Oct 27, 2026 9:25 PM
44Insider Transaction0001193125-26-410839Oct 1, 2026 1:20 AM
5144Insider Transaction0001969223-26-001047Oct 1, 2026 12:10 AM
6SCHEDULE 13GBeneficial Ownership Report0000080255-26-000601Sep 8, 2026 1:42 PM
74Insider Transaction0001193125-26-383874Sep 4, 2026 10:00 PM
8144Insider Transaction0001193125-26-383667Sep 4, 2026 8:15 PM
9144Insider Transaction0001950047-26-009024Sep 2, 2026 8:32 PM
10SCHEDULE 13GBeneficial Ownership Report0000080255-26-000572Aug 14, 2026 2:38 PM
11SCHEDULE 13GBeneficial Ownership Report0001628098-26-000009Aug 13, 2026 8:42 PM
1210-QQuarterly & Annual Report0001193125-26-333849Aug 5, 2026 11:15 AM
138-KCurrent Report0001193125-26-333834Aug 5, 2026 11:10 AM
144Insider Transaction0001193125-26-318408Jul 27, 2026 10:34 PM
153Insider Transaction0001193125-26-318404Jul 27, 2026 10:25 PM
168-KCurrent Report0001193125-26-318078Jul 27, 2026 8:10 PM
174Insider Transaction0001193125-26-297817Jul 7, 2026 12:00 AM
18144Insider Transaction0001969223-26-000769Jul 7, 2026 8:07 PM
194Insider Transaction0001193125-26-295090Jul 2, 2026 10:30 PM
204Insider Transaction0001193125-26-295089Jul 2, 2026 10:30 PM
214Insider Transaction0001193125-26-295088Jul 2, 2026 10:30 PM
224Insider Transaction0001451612-26-000022Jul 2, 2026 9:39 PM
23144Insider Transaction0001969223-26-000752Jul 2, 2026 12:33 PM
24144Insider Transaction0001950047-26-006765Jul 1, 2026 8:58 PM
254Insider Transaction0001451612-26-000020Jun 30, 2026 9:32 PM
264Insider Transaction0001451612-26-000018Jun 30, 2026 9:30 PM
27144Insider Transaction0001950047-26-006647Jun 30, 2026 8:32 PM
28144Insider Transaction0001628280-26-046098Jun 29, 2026 9:51 PM
29144Insider Transaction0001628280-26-046097Jun 29, 2026 9:51 PM
304Insider Transaction0000921895-26-001688Jun 26, 2026 10:48 PM
31SCHEDULE 13DBeneficial Ownership Report0000921895-26-001687Jun 26, 2026 10:43 PM
32144Insider Transaction0000921895-26-001685Jun 26, 2026 10:13 PM
33144Insider Transaction0001628280-26-045808Jun 26, 2026 8:52 PM
34144Insider Transaction0001628280-26-045807Jun 26, 2026 8:51 PM
354Insider Transaction0001451612-26-000016Jun 25, 2026 1:56 AM
364Insider Transaction0001451612-26-000015Jun 25, 2026 1:55 AM
374Insider Transaction0000921895-26-001680Jun 25, 2026 10:58 PM
384Insider Transaction0001193125-26-283141Jun 25, 2026 10:00 PM
394Insider Transaction0001193125-26-283140Jun 25, 2026 10:00 PM
404Insider Transaction0001193125-26-283139Jun 25, 2026 10:00 PM
414Insider Transaction0001193125-26-283136Jun 25, 2026 10:00 PM
424Insider Transaction0001193125-26-283138Jun 25, 2026 10:00 PM
434Insider Transaction0001193125-26-283135Jun 25, 2026 10:00 PM
444Insider Transaction0001193125-26-283137Jun 25, 2026 10:00 PM
454Insider Transaction0001193125-26-283134Jun 25, 2026 10:00 PM
46144Insider Transaction0001628280-26-045610Jun 25, 2026 9:26 PM
47144Insider Transaction0001628280-26-045609Jun 25, 2026 9:25 PM
484Insider Transaction0001193125-26-283039Jun 25, 2026 9:10 PM
49144Insider Transaction0001950047-26-006511Jun 25, 2026 8:27 PM
508-KCurrent Report0001193125-26-281817Jun 25, 2026 11:10 AM
...

Kymera Therapeutics, Inc. SEC Filings API

Pull Kymera Therapeutics, Inc.'s SEC filing index, with links to every filing and exhibit, into your own tools with the Business Quant SEC Filings API. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/secfilings?ticker=KYMR&formtype=10-K,10-Q&api_key=YOUR_API_KEY